Elutia Inc.
ELUT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708527
No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Elutia Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 17 | 19 | +2 |
| Shares | 3.33M | 4.34M | +1.01M (+30.2%) |
| Value | $24.0M | $18.4M | −$5.55M (−23.1%) |
New holders (4)
Institutions that held Elutia Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alyeska Investment Group, L.P. | 250,000 | $1.06M | 0.01% |
| Prosight Management, LP | 185,014 | $786.3K | 0.44% |
| Pentwater Capital Management LP | 125,000 | $531.3K | 0.02% |
| Knollwood Investment Advisory, LLC | 58,962 | $250.6K | 0.10% |
Sold out (2)
Institutions that held Elutia Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Millennium Management LLC | 11,586 | $83.0K |
| Royal Bank of Canada | 34 | $0 |